Cost of a 5-year lung cancer survivor: Symptomatic tumour identification vs proactive computed tomography screening

British Journal of Cancer

Volumn 101, Issue 6, 2009, Pages 882-886

  Castleberry, A W ^a   Smith, D ^b   Anderson, C ^c   Rotter, A J ^b   Grannis, F W ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Comparative effectiveness research; Computerised tomography; Cost effectiveness; Lung cancer; QALY; Screening

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL FEATURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MATHEMATICAL MODEL; MULTIDETECTOR COMPUTED TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SURVIVAL TIME;

ADULT; AGED; BIAS (EPIDEMIOLOGY); COST OF ILLNESS; COST-BENEFIT ANALYSIS; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SURVIVORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70249083339     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605253     Document Type: Article

References (47)

1. Adis International Ltd. Erlotinib (2003) CP 358774, NSC 718781, OSI 774, R 1415. Drugs R D 4(4): 243-248
2. American Cancer Society (2006) Cancer Facts and Figures 2006. Atlanta: American Cancer Society
3. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB (2007) Computed tomography screening and lung cancer outcomes. JAMA 297(9): 953-961 (Pubitemid 46376749)
4. Black C, Bagust A, Boland A, Walker S, McLeod C, De Verteuil R, Ayres J, Bain L, Thomas S, Godden D, Waugh N (2006) The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technol Assess 10(3): 8, 38
5. Centers for Disease Control and Prevention (2005) Annual Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses-United States, 1997-2001. MMWR 54: 625-628
6. Chien CR, Chen TH (2008) Mean sojourn time and effectiveness of mortality reduction for lung cancer screening with computed tomography. Int J Cancer 122(11): 2594-2599
7. Chirikos TN, Hazelton T, Tockman M, Clark R (2002) Screening for lung cancer with CT: a preliminary cost-effectiveness analysis. Chest 121: 1507-1514
8. Evans WK, Will BP, Berthelot JM, Wolfson MC (1995) Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol 5: 408-419
9. Fireman BH, Quesenberry CP, Somkin CP, Jacobson AS, Baer D, West D, Potosky AL, Brown ML (1997) Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 18: 51-76 (Pubitemid 27516400)
10. Flehinger BJ, Kimmel M, Melamed MR (1992) The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest 101(4): 1013-1018
11. Flieder DB, Vazquez M, Carter D, Brambilla E, Gazdar A, Noguchi M, Travis WD, Kramer A, Yankelevitz DF, Henschke CI (2006) Pathologic findings of lung tumors diagnosed on baseline CT screening. Am J Surg Pathol 30(5): 606-613
12. Fry WA, Phillips JL, Menck HR (1999) Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 86: 1867-1876
13. Henschke CI (2006) International early lung cancer action program: protocol. http://www.ielcap.org/ielcap.pdf,10/20/2006. Accessed 26 December 2006.
14. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK, Smith JP (1999) Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 354: 99-105
15. Henschke CI, Naidich DP, Yankelevitz DF, McGuinness G, McCauley DI, Smith JP, Libby D, Pasmantier M, Vazquez M, Koizumi J, Flieder D, Altorki N, Miettinen OS (2001) Early lung cancer action project. Initial findings on repeat screenings. Cancer 92: 153-159 (Pubitemid 32623052)
16. Henschke CI, Smith JP, Miettinen OS (2007) Response to letters to the editor. N Engl J Med 356: 743-747
17. Henschke CI, Wisnivesky JP, Yankelevitz DF, Miettinen OS (2003) Small stage I cancers of the lung: genuineness and curability. Lung Cancer 39(3): 327-330
18. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS (2006a) Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355(17): 1763-1771
19. Henschke LI, Yankelevitz DF (2008) CT screening for lung cancer: Update 2007. Oncologist 13: 65-78
20. Horton JA, Cruess DF, Romans MC (1996) Compliance with mammo-graphy screening guidelines: 1995 mammography attitudes and usage study report. Womens Health Issues 6: 239-245
21. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10-30
22. Kappauf H, Gallmeier WM, Wünsch PH (1997) Complete spontaneous remission in a patient with metastatic non-small-cell lung cancer. Case report, review of literature, and discussion of possible biological pathways involved. Ann Oncol 8(10): 1031-1039
23. Kelly RF, Tran T, Holmstrom A, Murar J, Segurola Jr RJ (2004) Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 125: 1413-1423
24. Knudsen AB, McMahon PM, Gazelle GS (2007) Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol 25(2): 203-208
25. Langer CJ, Moughan J, Movsas B, Komaki R, Ettinger D, Owen J, Wilson JF (2005) Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature? Lung Cancer 48(1): 93-102
26. Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR (2003) Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 289: 313-322
27. Marcus PM, Bergstralh EJ, Fagerstrom RM, Williams DE, Fontana R, Taylor WF, Prorok PC (2000) Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 92: 1308-1316
28. Marshall D, Simpson KN, Earle CC, Chu CW (2001a) Economic decision analysis model of screening for lung cancer. Eur J Cancer 37: 1759-1767
29. Marshall D, Simpson KN, Earle CC, Chu C (2001b) Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort. Lung Cancer 32: 227-236
30. Morrison AS (1982) The effects of early treatment, lead time and length bias on the mortality experienced by cases detected by screening. Int J Epidemiol 11: 261-267
31. Muntain CF (1997) Revisions in the International System for staging lung cancer. Chest 111(6): 1710-1717
32. National Cancer Institute (2005) Surveillance, Epidemiology, and End Results (SEER) Program, (www.seer.cancer.gov) Public-Use Data (1973-2003), DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
33. National Cancer Institute (2003) Centers for Disease Control and Prevention Co-sponsored Tobacco Use Special Cessation Supplement to the Current Population Survey. http://riskfactor.cancer.gov/studies/tus-cps/.
34. Patz Jr EF (2006) Lung cancer screening, overdiagnosis bias, and reevalu-ation of the Mayo Lung Project. J Natl Cancer Inst 98(11): 724-725
35. Patz Jr EF, Rossi S, Harpole Jr DH, Herndon JE, Goodman PC (2000) Correlation of tumor size and survival in patients with pathologic stage lA nonsmall cell lung cancer. Chest 117: 1568-1571
36. Phillips C, Thompson G (2003) What is a QALY? Newmarket, United Kingdom: Hayward Medical Communications; 2003. www.evidence-based-medicine.co.uk.Accessed 8 September 2006.
37. Phillips KA, Kerlikowske K, Baker LC, Chang SW, Brown ML (1998) Factors associated with women's adherence to mammography screening guidelines. Health Serv Res 33: 29-53
38. Rahman SM, Dignan MB, Shelton BJ (2003) Factors influencing adherence to guidelines for screening mammography among women aged 40 years and older. Ethn Dis 13: 477-484
39. Ramsey SD, Howlader N, Etzioni RD, Donato B (2004) Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 22(24): 4971-4978
40. Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM (2007) Natural history of stage I non-small cell lung cancer: implications for early detection. Chest 132(1): 193-199
41. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK(eds) (2005) SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975-2003/, based on November 2005 SEER data submission, posted to the SEER web site, 2006.
42. Riley GF, Potosky AL, Lubitz JD, Kessler LG (1995) Medicare payments from diagnosis to death for elderly cancer patients by stage of diagnosis. Med Care 33: 828-841
43. Sobue T, Moriyama N, Kaneko M, Kusumoto M, Kobayashi T, Tsuchiya R, Kakinuma R, Ohmatsu H, Nagai K, Nishiyama H, Matsui E, Eguchi K (2002) Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 20: 911-920
44. Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, Sykes AM, Aughenbaugh GL, Zink FE, Hillman SL, Noetzel GR, Marks RS, Clayton AC, Pairolero PC (2002) Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 165: 508-513
45. Whynes DK (2008) Could CT screening for lung cancer ever be cost effective in the United Kingdom? Cost Eff Resour Alloc 6: 5
46. Wisnivesky JP, Mushlin AI, Sicherman N, Henschke C (2003) The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening. Chest 124: 614-621
47. Yankelevitz DF, Kostis WJ, Henschke CI, Heelan RT, Libby DM, Pasmantier MW, Smith JP (2003) Overdiagnosis in chest radio-graphic screening for lung carcinoma: frequency. Cancer 97(5): 1271-1275